As Off-Label Use Spreads, Supplies Of Niche Drugs And Patients’ Patience Grow Short
The reasons behind one particular shortage of a therapy known as IVIG are complicated, stemming from increased demand and the medication’s long production window.
The independent source for health policy research, polling, and news.
Showing 181 - 200 of 585
The reasons behind one particular shortage of a therapy known as IVIG are complicated, stemming from increased demand and the medication’s long production window.
With nearly 72% of U.S. adults considered overweight or obese, the pressing question is: Is it possible to be overweight and healthy at the same time? The science falls short.
New research published in JAMA Network Open quantified for the first time international differences in doctors’ prescribing habits and patients’ use of these highly addictive painkillers.
In the background, advisers weigh the risks of rolling out a comprehensive health care proposal. Peering into the crystal ball, here’s a glimpse of what could be included in the GOP plan.
Research out Wednesday indicates that guidelines are making strides in cutting back the number of pain pills doctors offer after specific types of surgeries.
Residents in Colorado ski resort country found relief from high insurance premiums and high hospital costs by joining forces and negotiating prices directly with the local hospital.
The proposed rules would require hospitals to provide far more detail about the actual prices they charge insurers for patients’ care.
The drug industry has the biggest lobbying war chest.
KHN consulted legal experts about some of the arguments advanced by Trump administration lawyers during the most recent round of oral arguments in the legal challenge brought by 18 “red” states to overturn the Affordable Care Act.
Guess who’s back grabbing headlines? Pharmacy benefit managers — those companies that serve as middlemen in the prescription drug pipeline.
President Donald Trump ordered the federal government to help consumers benefit from gaining fuller estimates about their health care costs. But whether it will be a game changer depends on the details.
A new data analysis by KHN and Johns Hopkins researchers shows that even as the CDC issued warnings, surgeons handed out many times the number of opioid pills needed for post-op pain.
People who buy insurance on their own may have little notice when something goes amiss. It’s a quirk in health policy at the heart of the next episode of ‘An Arm and a Leg’ podcast.
An array of products — from mattresses and sensors to sleep trackers and apps — are catching consumers’ attention. But privacy experts are concerned about what becomes of all the personal information these products collect.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
Judge cited an attempted “end-run” around the Affordable Care Act in rejecting large chunks of a new rule expanding access to such plans for small businesses and single proprietors.
New research published in JAMA detected some changes in healthy behavior like weight and stress, but little overall impact in workers’ health status or employer health care spending.
Some plans are experimenting with the idea of closely tying hospital reimbursement rates to what Medicare pays. The approach could be a game changer in their effort to control health costs.
These direct-enrollment broker websites are “under-policed” and can steer consumers toward plans that may not be the best option for them, a new report concludes.
Well-known insurers are offering plans with lower premiums. But they could leave patients on the hook for unexpected costs.
Stay informed by signing up for the Morning Briefing and other emails:
© 2026 KFF